Frontline Enfortumab Vedotin Plus Pembrolizumab Elicits OS Improvement in Advanced Urothelial Carcinoma
Frontline treatment with the combination of enfortumab vedotin-ejfv and pembrolizumab led to a statistically significant improvement in overall survival vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.
Lenvatinib Plus Pembrolizumab Maintains Survival Benefit in Advanced RCC
Lenvatinib plus pembrolizumab (Keytruda) showed a sustained overall survival and progression-free survival benefit vs sunitinib alone at a median follow-up of 4 years in patients with advanced renal cell carcinoma.
Belzutifan/Lenvatinib Elicits Responses in Advanced ccRCC After Progression on ICI and VEGF TKI
Belzutifan plus lenvatinib generated responses and displayed a manageable safety profile in patients with advanced clear cell renal cell carcinoma whose disease progressed following treatment with a PD-1/L1 inhibitor and a VEGF TKI.
Apalutamide Plus ADT Improves PSA PFS in Biochemically Relapsed Prostate Cancer
Apalutamide plus androgen deprivation therapy with or without abiraterone acetate and prednisone improved prostate-specific antigen progression-free survival in patients with biochemically relapsed prostate cancer, according to long-term follow-up data from the phase 3 PRESTO trial.
Darolutamide Plus ADT Elicits OS Benefit in North American Patients With mHSPC
A subgroup analysis of the phase 3 ARASENS trial showed that darolutamide plus androgen deprivation therapy elicited an overall survival benefit in North American patients with metastatic hormone-sensitive prostate cancer.
Zoledronic Acid Lowers Risk of Fracture in mHSPC
The use of zoledronic acid or other bisphosphonates was associated with a significant reduction in risk of fracture in patients with metastatic hormone-sensitive prostate cancer.
Apalutamide Plus ADT Elicits PSA PFS Benefit in High-Risk, Biochemically Relapsed Prostate Cancer
Intensification of androgen-deprivation therapy plus apalutamide displayed promising efficacy in patients with high-risk, biochemically relapsed prostate cancer.
Atezolizumab Fails to Improve DFS in RCC Following Resection
Treatment with atezolizumab did not improve clinical outcomes vs placebo following resection in patients with renal cell carcinoma at increased risk of recurrence.
Select Biomarkers Signal Worse Survival Outcomes With Apalutamide/ADT in mCSPC
Circulating tumor DNA, select androgen receptor, and non-AR biomarkers have been identified as potential prognostic indicators of overall survival benefit for apalutamide plus androgen-deprivation therapy for patients with metastatic castration-sensitive prostate cancer.
PSMA-PET Imaging Parameters Shown to Identify Optimal Population for 177Lu-PSMA-617 Treatment in mCRPC
68Ga-PSMA-11 PET/CT imaging parameters demonstrated a statistically significant association with clinical outcomes with the PSMA-targeted radioligand therapy lutetium-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
TMB Serves as Predictive Biomarker of Toripalimab Efficacy in Urothelial Carcinoma
Tumor mutational burden served as a prognostic indicator of the efficacy of toripalimab among Chinese patients with urothelial carcinoma.
Atezolizumab Plus Cabozantinib Elicits Clinical Activity in Advanced Urothelial Cancer
Cabozantinib plus atezolizumab demonstrated promising clinical activity and a suitable safety profile as first-line therapy in patients with cisplatin- eligible and -ineligible, inoperable locally advanced or metastatic urothelial cancer and as second- or later-line therapy in those who received a prior immune checkpoint inhibitor, according to findings from the phase 1b COSMIC-021 trial.
Neoadjuvant Axitinib Effective in Subgroup of Patients with Renal Cell Carcinoma
Neoadjuvant axitinib facilitated partial nephrectomy in patients with clear cell renal cell carcinoma and complex masses with an imperative indication for nephron-sparing surgery but no viable pathway to receive the procedure.
Darolutamide Demonstrates Strong Safety Profile in mCRPC after Long-Term Analyses
Darolutamide produced a well-tolerated safety profile in patients with metastatic castration-resistant prostate cancer, according to pooled data from long-term analyses of 3 trials.
Olaparib Plus Bipolar Androgen Therapy Showcases Clinical Activity Within Prostate Cancer
Combining the PARP inhibitor olaparib with bipolar androgen therapy demonstrated promising clinical activity in patients with castration-resistant prostate cancer.
TAK-700 Plus ADT Significantly Improves PFS and PSA Responses in mHSPC, But Not OS
The addition of TAK-700 to androgen-deprivation therapy improved median progression-free survival and prostate-specific antigen responses, but did not significantly improve overall survival vs ADT and bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer.
TURBT Plus Nivolumab/Chemo Shows Promise in Muscle-Invasive Bladder Cancer
Combining transurethral resection of the bladder tumor with nivolumab and chemotherapy showed promise as a bladder-sparing treatment strategy in patients with muscle-invasive bladder cancer.
Pembrolizumab/Axitinib Survival Benefit Sustained in Long-Term Results in RCC
The frontline combination of pembrolizumab plus axitinib continued to show a survival benefit over single-agent sunitinib in patients with renal cell carcinoma.
Increased PSA Screening Reduces Prostate Cancer–Specific Mortality in Younger African Americans
An increase in the frequency of prostate-specific antigen (PSA) screening was associated with a nearly 25% reduction in prostate cancer–specific mortality in younger African Americans, according to data from a study presented in a presscast held ahead of the 2021 ASCO Annual Meeting.
Talazoparib Most Likely to Induce Response in mCRPC With Germline and/or Homozygous tDDR Alterations
Patients with heavily pretreated metastatic castration-resistant prostate cancer who have germline and/or homozygous tumor DNA damage response alterations have been shown to have a higher likelihood of responding to treatment with talazoparib.
PSMA PET Imaging Agent 18F-DCFPyL Demonstrates High CLR and PPV
February 13, 2021 - 18F-DCFPyL, an investigational prostate-specific membrane antigen PET imaging agent, was found to detect and localize metastatic lesions with a high correct localization rate and positive predictive value.
Apalutamide Plus Abiraterone Reduces Risk of Progression in mCRPC
February 11, 2021 - Adding apalutamide to abiraterone acetate and prednisone reduced the risk of radiographic progression or death by 30% in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer receiving androgen deprivation therapy.
FDA Approves Multiple Companion Diagnostics for Olaparib in HRR+ mCRPC
The FDA has approved the FoundationOneCDx and BRACAnalysis CDx tests as companion diagnostics to identify patients with metastatic castration-resistant prostate cancer with homologous recombination repair mutations, making them eligible for treatment with the PARP inhibitor olaparib.
FDA Approves Frontline Atezolizumab for PD-L1–High NSCLC
The FDA has approved single-agent atezolizumab as a frontline treatment for patients with advanced non–small cell lung cancer with high PD-L1 expression.
Alvocidib Trial Launches in MDS
The first patient has been diagnosed with alvocidib, administered in sequence following azacitidine, in the expansion of the phase 1b/2 Zella 102 study in patients with myelodysplastic syndromes.
Study of Anti-CD73 Immunotherapy TJD5 in Solid Tumors Launches in China
The first patient has been dosed in a phase 1/2 trial of TJD5 in Chinese patients with advanced solid tumors, according to I-Mab, the company developing the CD73 antibody.
TAS-102 Plus Bevacizumab Is Potential New Option in Refractory mCRC
The addition of bevacizumab to TAS-102 (trifluridine/tipiracil; Lonsurf) reduced the risk of disease progression or death compared with TAS-102 alone in patients with chemorefractory metastatic colorectal cancer.
Cediranib/Olaparib Combo Falls Short in Phase III Relapsed Ovarian Cancer Trial
Cediranib plus olaparib did not lead to a statistically significant improvement in progression-free survival compared with platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer.
Frontline Venetoclax/Obinutuzumab Approved in Europe in CLL
The European Commission has approved a fixed-dose combination of venetoclax and obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia.
Cirmtuzumab/Ibrutinib Combo Active in Mantle Cell Lymphoma
Combination therapy with cirmtuzumab and ibrutinib induced a 50% complete response rate in the phase I/II CIRLL study.
Dr Cook on Real-World Data With Bridging Therapy and Axi-Cel in Relapsed/Refractory LBCL
Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL
Ide-Cel Provides HRQOL Benefits Over Standard Regimens in R/R Multiple Myeloma
Bridging Therapy Prior to Axi-Cel Produces Favorable Real-World Outcomes in R/R LBCL
2 Clarke Drive Cranbury, NJ 08512